Compare Boston Scientific Corporation (BSX) vs Fastly Inc (FSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Fastly Inc — how do they compare? Boston Scientific Corporation trades at $42.97 (market cap $66.37B), while Fastly Inc trades at $20.01 (market cap $3.27B). The key difference: Boston Scientific Corporation is far larger — about 20.3× Fastly Inc's market cap, and Fastly Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | FSLY | |
|---|---|---|
Market Cap | $66.37B | $3.27B |
Sector | Health | Technology |
52-Week High | $108.14 | $33.50 |
52-Week Low | $42.63 | $6.36 |
Enterprise Value | $75.94B | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Fastly (FSLY) trades at $20.03, up 2.25% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.13 versus $0.08, and revenue growth accelerating to 20% year-over-year. Recent news highlights strategic partnerships for digital sustainability and edge AI commerce, while cash flow trends indicate potential stabilization with 2026 net cash flow projected positive at $21 million.
Outlook remains cautiously optimistic with a consensus price target of $24.25 offering 21% upside, though persistent net losses and negative ROE pose risks. Investor sentiment is mixed with 29% buy ratings amid competitive pressures in edge cloud services. Key catalysts include Q2 2026 earnings on August 5 and execution on margin expansion targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
